Reinforcing the Value of Combination Therapy to Treat Moderate to Severe Alzheimer’s Disease

Combination therapy with memantine was associated with sustained benefits in cognition and function over time.

Combination Therapy: Optimizing the Treatment
of Moderate to Severe Alzheimer’s Disease

Special Issue: This content represents an Educational
Service brought to you by Forest Pharmaceuticals, Inc.

An Update on Sunitinib as First-Line
Therapy for Metastatic RCC

Data demonstrate that treatment-naïve patients with metastatic renal-cell carcinoma, or mRCC, who received sunitinib malate had longer progression-free survival and higher response ...